Skip to content

Regado Biosciences receives securities class action lawsuit

A law office recently announced that it filed a securities class action lawsuit against a biopharmaceutical company due to allegations of federal securities law violations.

Law firm Pomerantz, LLP, filed the litigation in the U.S. District Court for the District of New Jersey against Regado Biosciences, Inc. This includes all shareholders who purchased interests in the company during the class period between Aug. 22, 2013 and July 9, 2014.

The lawsuit had multiple allegations against the company that revolved around potential violations of the Securities Exchange Act of 1934. Specifically, there were a number of statements made by Regado Biosciences' board of directors that may have been either false or misleading regarding the business prospects and operations of the company.

It is an option for shareholders to become lead plaintiff in the case, and those interested parties must take action with the court by Sept. 8, 2014. This is not a mandatory action, and shareholders still have the ability to remain absent class members by taking no further steps at this time. Any applicants will need to be approved by the court as adequate representatives of the class.

For shareholders that want to learn more about the lead plaintiff position, or would like to discuss how their rights or interests may be affected by the pending litigation, speaking with the law office is a possibility. Robert Willoughby is the best person to contact, and he can be reached by telephone or email. Any shareholders who send an email need to leave their mailing address, telephone number and the number of Regado Biosciences shares that they own.

Second law office begins investigation
Another litigation firm noted that it was looking into the situation involving the leaders at Regado Biosciences. There is a possibility that this could become a class action lawsuit at a later date.

The Rosen Law Firm, P.A., noted that it started investigating Regado Biosciences for many of the aforementioned reasons. These issues stemmed from statements made during the company's phase three clinical trials.

It is also an option for stockholders to discuss matters with this law firm if they purchased interests in Regado Biosciences before July 3, 2014. Both Phillip Kim and Kevin Chan are available to speak about the investigation, and can be reached by telephone or email. There is also further detail posted on the law office's website.

Scroll To Top